NAT10-mediated ac4C modification has emerged as a critical driver of tumorigenesis, with elevated NAT10 expression observed in 92% of cancers and strongly correlating with poor prognosis across malignancies [93–102]. The gene discussed is NAT10; the disease is cancer.